Market Applicability				
Market	**GA**	**MD**	**NJ**	**NY**
Applicable	NA	NA	X	NA

Spravato (esketamine) nasal spray

NJ Medicaid

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Treatment resistant depression: Initial approval: 3 months Maintenance approval: 12 months

New Jersey Medicaid

Medications	Quantity Limit
Spravato (esketamine) nasal spray 56 mg Dose Kit, 84 mg Dose Kit	4 kits per 28 days*

*Initiation of therapy for Spravato (esketamine): May approve up to 4 additional kits in the first month (28 days) of treatment.

APPROVAL CRITERIA

1. Patient is 18 years of age or older **AND**

2. Patient has been diagnosed with treatment-resistant depression **AND**

3. There is documentation showing that the patient had therapeutic failure or had an intolerance for at least 3 weeks each to at least two (2) antidepressants unless the patient has contraindications to all antidepressants. **AND**

4. Patient must use Spravato nasal spray in conjunction with an oral antidepressant therapy **AND**

5. Spravato will be administered under the supervision of a healthcare provider and the patient will be monitored for at least 2 hours after administration **AND**

6. Patient has been assessed and determined not to be at risk for abuse and misuse of Spravato **AND**

7. Patient has no contraindications to therapy: a. Patient has no aneurysmal vascular disease (including in the brain, chest, abdominal aorta, arms and legs) or arteriovenous malformation, or history of bleeding in the brain

Market Applicability				
Market	**GA**	**MD**	**NJ**	**NY**
Applicable	NA	NA	X	NA

Continuation of therapy:

1. Documentation showing the patient responded to therapy demonstrated by an improvement from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS)

Warning: Because of the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS

References:

1. Spravato [package insert]. Janssen Pharmaceuticals, Inc., Titusville, NJ 08560. March 2019
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2018. Updated periodically
3. Canuso C, Singh J, et al: Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018. Accessed online on May 24, 2019 at: https://adaa.org/sites/default/files/Canuso-AJP-2018.pdf

State Specific Mandates		
New Jersey	08/01/2021	